首页|期刊导航|Cancer Innovation|Expert Consensus on the Clinical Application of Poly ADP Ribose Polymerase Inhibitors in Breast Cancer(2025 Edition)

Expert Consensus on the Clinical Application of Poly ADP Ribose Polymerase Inhibitors in Breast Cancer(2025 Edition)OA

中文摘要

Breast cancer represents a major threat to women's health in China.Its continuously rising incidence contributes to a growing disease burden,thereby creating a critical demand for novel and effective therapeutic strategies.In recent years,poly ADP-ribose polymerase(PARP)inhibitors,as a novel class of anti-tumor drugs targeting the DNA damage repair pathway,have demonstrated remarkable efficacy in treating breast cancer with BRCA1/2 mutations.By selectively inhibiting DNA repair in tumor cells,these agents induce a“synthetic lethality”effect,offering a new option for precision therapy.Currently,PARP inhibitors such as Olaparib and Fluzoparib have been approved for clinical use.This consensus,based on the latest evidence-based medical data,provides guidance on the standardized application and safety management of PARP inhibitors in breast cancer treatment,aiming to serve as a reference for clinical practice.

Fei Ma;Binghe Xu;China Anti-Cancer Association Committee on Clinical Research of Anticancer Drugs;National Expert Committee on Monitoring Clinical Application of Antineoplastic Drugs;Breast Cancer Expert Committee of National Cancer Quality Control Center;Expert Committee on Chemotherapy Quality Control of Beijing Cancer Treatment Quality Control and Improvement Center

Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,ChinaDepartment of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,China

医药卫生

breast cancerclinical applicationPARP inhibitorssafety managementtargeted therapy

《Cancer Innovation》 2026 (3)

P.9-19,11

Noncommunicable Chronic Diseases-National Science and Technology Major Project,Grant/Award Number:2023ZD0502200National Natural Science Foundation of China,Grant/Award Number:92459304Major Collaborative Innovation Project of the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences,Grant/Award Number:2022-I2M-2-001。

10.1002/cai2.70062

评论